Zobrazeno 1 - 10
of 156
pro vyhledávání: '"Steven Attia"'
Autor:
Lan Gao, Diksha Kaushik, Brian A. Van Tine, Matthew A. Ingham, Steven Attia, Christian F. Meyer, Gary K. Schwartz, Pius Maliakal, John D. Baird, Jiyuan Ma, Rosemary Barrett, Dhiren D'Silva, Kylie O'Keefe, Ronald Kong
Publikováno v:
Clinical and Translational Science, Vol 17, Iss 2, Pp n/a-n/a (2024)
Abstract Unesbulin is being investigated in combination with dacarbazine (DTIC) as a potential therapeutic agent in patients with advanced leiomyosarcoma (LMS). This paper reports the pharmacokinetics (PK) of unesbulin, DTIC, and its unreactive surro
Externí odkaz:
https://doaj.org/article/67669181c17b40ddb322ddfc3dd1c1a1
Autor:
Steven Attia, Vanessa Bolejack, Kristen N. Ganjoo, Suzanne George, Mark Agulnik, Daniel Rushing, Elizabeth T. Loggers, Michael B. Livingston, Jennifer Wright, Sant P. Chawla, Scott H. Okuno, Denise K. Reinke, Richard F. Riedel, Lara E. Davis, Christopher W. Ryan, Robert G. Maki
Publikováno v:
Cancer Medicine, Vol 12, Iss 2, Pp 1532-1539 (2023)
Abstract Background Regorafenib is one of several FDA‐approved cancer therapies targeting multiple tyrosine kinases. However, there are few subtype‐specific data regarding kinase inhibitor activity in sarcomas. We report results of a single arm,
Externí odkaz:
https://doaj.org/article/124378635bd247fb9b2242a52cc12063
Autor:
Patrick Schöffski, Suzanne George, Michael C. Heinrich, John R. Zalcberg, Sebastian Bauer, Hans Gelderblom, César Serrano, Robin L. Jones, Steven Attia, Gina D’Amato, Ping Chi, Peter Reichardt, Claus Becker, Kelvin Shi, Julie Meade, Rodrigo Ruiz-Soto, Jean-Yves Blay, Margaret von Mehren
Publikováno v:
BMC Cancer, Vol 22, Iss 1, Pp 1-10 (2022)
Abstract Background Ripretinib is a novel switch-control kinase inhibitor that inhibits KIT and PDGFRA signaling. In the INVICTUS phase 3 trial, ripretinib increased median progression-free survival and prolonged overall survival vs. placebo in ≥ f
Externí odkaz:
https://doaj.org/article/9bb5658e944d433ba93df74a037e4505
Autor:
Mrinal M. Gounder, Narasimhan P. Agaram, Sally E. Trabucco, Victoria Robinson, Richard A. Ferraro, Sherri Z. Millis, Anita Krishnan, Jessica Lee, Steven Attia, Wassim Abida, Alexander Drilon, Ping Chi, Sandra P. D’ Angelo, Mark A. Dickson, Mary Lou Keohan, Ciara M. Kelly, Mark Agulnik, Sant P. Chawla, Edwin Choy, Rashmi Chugh, Christian F. Meyer, Parvathi A. Myer, Jessica L. Moore, Ross A. Okimoto, Raphael E. Pollock, Vinod Ravi, Arun S. Singh, Neeta Somaiah, Andrew J. Wagner, John H. Healey, Garrett M. Frampton, Jeffrey M. Venstrom, Jeffrey S. Ross, Marc Ladanyi, Samuel Singer, Murray F. Brennan, Gary K. Schwartz, Alexander J. Lazar, David M. Thomas, Robert G. Maki, William D. Tap, Siraj M. Ali, Dexter X. Jin
Publikováno v:
Nature Communications, Vol 13, Iss 1, Pp 1-15 (2022)
Comprehensive molecular profiles are required to understand and treat sarcomas, which comprise more than 70 different subtypes. Here, the authors profile the genomic landscape of 7494 sarcomas across 44 histologies using targeted panel sequencing and
Externí odkaz:
https://doaj.org/article/ded28dd2538e4114ba7de3e78b153f38
Autor:
Seth M. Pollack, Neeta Somaiah, Dejka M. Araujo, Mihaela Druta, Brian A. Van Tine, Melissa A. Burgess, Sant P. Chawla, Mahesh Seetharam, Scott H. Okuno, Chet Bohac, Michael Chen, Sergey Yurasov, Steven Attia
Publikováno v:
Cancer Medicine, Vol 9, Iss 13, Pp 4593-4602 (2020)
Abstract Background Outcomes data regarding advanced synovial sarcoma (SS) and myxoid/round cell liposarcoma (MRCL) are limited, consisting primarily of retrospective series and post hoc analyses of clinical trials. Methods In this multi‐center ret
Externí odkaz:
https://doaj.org/article/2292b5dd195549049e097c6c426bed12
Autor:
Sanjay P. Bagaria, Zoran Gatalica, Todd Maney, Daniel Serie, Mansi Parasramka, Steven Attia, Murli Krishna, Richard W. Joseph
Publikováno v:
Frontiers in Oncology, Vol 8 (2018)
Angiosarcoma is a vascular malignancy associated with a poor prognosis and chemotherapy resistance. The tumor immune microenvironment of angiosarcoma has not been characterized. We investigated the expression of programmed death-ligand 1 (PD-L1) and
Externí odkaz:
https://doaj.org/article/e390505e71f846398902a4707642f54c
Autor:
Sanjay P. Bagaria, Yu-Hui Chang, Richard J. Gray, Jonathan B. Ashman, Steven Attia, Nabil Wasif
Publikováno v:
Sarcoma, Vol 2018 (2018)
Introduction. Optimization of outcomes of extra-abdominal STS is not clearly understood. We sought to determine whether hospital surgical volume and adherence to NCCN guidelines, or both, are associated with outcomes in the treatment of extra-abdomin
Externí odkaz:
https://doaj.org/article/80c77ab045cc4f9c95d1c134c5bd4b5c
Autor:
Jaime I. Davila, Jason S. Starr, Steven Attia, Chen Wang, Ryan A. Knudson, Brian M. Necela, Vivekananda Sarangi, Zhifu Sun, Yingxue Ren, John D. Casler, David M. Menke, Gavin R. Oliver, Richard W. Joseph, John A. Copland, Alexander S. Parker, Jean-Pierre A. Kocher, E. Aubrey Thompson, Robert C. Smallridge, Yan W. Asmann
Publikováno v:
Rare Tumors, Vol 9, Iss 2 (2017)
We previously reported an extremely rare case of follicular dendritic cell sarcoma (FDCS) presented as a thyroid mass. Given the rarity of this disease, there are no personalized and molecularly targeted treatment options due to the lack of knowledge
Externí odkaz:
https://doaj.org/article/a26f95a3211d4e78b5fdc2a9ee41b2f6
Autor:
Christopher L. Brett, Daniel H. Miller, Liuyan Jiang, Herbert C. Wolfsen, Steven Attia, Lauren Hintenlang, Niveditha Jagadesh, Robert C. Miller
Publikováno v:
Rare Tumors, Vol 8, Iss 4 (2016)
Soft tissue sarcomas of the esophagus represent an extremely rare cause of esophageal masses, and an even smaller proportion of these tumors represent dedifferentiated liposarcomas. We present a case of a 75-yearold gentleman presenting with dysphagi
Externí odkaz:
https://doaj.org/article/889a38d9671641518dbfd588cfec2025
Autor:
Tasneem A. Kaleem, Michael H. Schild, Daniel Miller, Asit Jha, Cherise Cortese, Steven Attia, Robert C. Miller
Publikováno v:
Rare Tumors, Vol 8, Iss 1 (2016)
Langerhan’s cell sarcoma (LCS) is a rare neoplasm with a poor prognosis. To our knowledge, only sixty-six cases have been published. We discuss two patients who presented very differently with LCS, as well as a recently published review of all sixt
Externí odkaz:
https://doaj.org/article/12a16c2416244a3d90098a3978ebafb0